Currently submitted to: Interactive Journal of Medical Research
Date Submitted: Aug 25, 2026
Open Peer Review Period: Sep 16, 2026 - Nov 11, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic versus Non-Diabetic Chronic Kidney Disease Patients
ABSTRACT
Background:
Chronic kidney disease (CKD) constitutes a prominent issue in global public health challenges, commonly caused by diabetes. Sodium glucose co-transporter 2 (SGLT2) inhibitors provide both renal and cardiovascular preservation in addition to lowering blood glucose levels.
Objective:
The purpose of the study was to compare the influence of SGLT2 inhibitors on renal function, as measured by eGFR, in Diabetic type II CKD individuals and non-diabetic CKD individuals.
Methods:
This case-control study was done on 60 adult CKD individuals with stage 3 and 4 (eGFR>_20ml/min/1.73 m2) according to the KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt. This study was executed on 60 adult CKD individuals with stage 3 and 4 (eGFR>_20ml/min/1.73 m2) according to the KIDGO classification. Participants were placed into two equal groups (GPs): GP I: CKD with T2DM and GP II: CKD and non-DM.
Results:
Mean percentage change in SBP and DBP, weight, eGFR, HbA1c, and ACR were comparable without significant differences between the groups. eGFR was comparable without a significant difference between the two groups. HbA1c was significantly higher in GP I than in GP II (P<0.001). There was a significant rise in eGFR, HbA1c, and ACR at baseline compared to after 24 weeks (P<0.001).
Conclusions:
SGLT2 inhibitors have been unequivocally demonstrated in this study to improve kidney-related outcomes in individuals with CKD and DKD. Furthermore, they optimize glomerular hemodynamic performance function and glycemic control, while significantly declining proteinuria and attenuating the progression of CKD. Clinical Trial: The study was registered at clinicaltrials.gov on 1 October 2024 (ID: NCT07302464).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.